Benzinga··BenzingaBiogen Closes $41-Per-Share Acquisition of Apellis, Adding $689M Revenue Pipeline
Biogen closes Apellis acquisition at $41/share, gaining two commercial products with $689M in 2025 revenue. Deal expected accretive to EPS by 2027.
APLSBIIBacquisitionM&A